Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

Shannon Puhalla,1 Sharon Wilks,2 Adam M Brufsky,1 Joyce O’Shaughnessy,3 Lee S Schwartzberg,4 Erhan Berrak,5 James Song,5 Linda Vahdat6 1Department of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Hematology Oncology, US Oncology-Cancer Car...

Full description

Bibliographic Details
Main Authors: Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L
Format: Article
Language:English
Published: Dove Medical Press 2016-12-01
Series:Breast Cancer : Targets and Therapy
Subjects:
oncology
breast neoplasms
advanced breast cancer
chemotherapy
eribulin mesylate
trastuzumab
Online Access:https://www.dovepress.com/clinical-effects-of-prior-trastuzumab-on-combination-eribulin-mesylate-peer-reviewed-article-BCTT

Internet

https://www.dovepress.com/clinical-effects-of-prior-trastuzumab-on-combination-eribulin-mesylate-peer-reviewed-article-BCTT

Similar Items